Clinical considerations for optimal use of the polymyxins: A focus on agent selection and dosing

Clinical Microbiology and Infection

Volumn 23, Issue 4, 2017, Pages 229-233

  Pogue, J M ^a,b   Ortwine, J K ^c,d   Kaye, K S ^e  

^a SINAI GRACE HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Colistin; Dosing; Efficacy; Gram negative; Nephrotoxicity; Polymyxin; Resistance

Indexed keywords

COLISTIN; POLYMYXIN B; ANTIINFECTIVE AGENT; POLYMYXIN;

COMPARATIVE EFFECTIVENESS; DRUG DOSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; KIDNEY; METABOLISM; MICROBIOLOGY; PATHOLOGY; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; COLISTIN; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; KIDNEY; POLYMYXINS; TREATMENT OUTCOME;

EID: 85015441618     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2017.02.023     Document Type: Review

References (28)

1. [1] Jones, T.S.G., The chemical basis for the classification of the polymyxins. Biochem J, 43(2), 1948, xxvi.
2. [2] Gales, A.C., Jones, R.N., Sader, H.S., Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–09). J Antimicrob Chemother 66 (2011), 2070–2074.
3. [3] Nation, R.L., Velkov, T., Li, J., Colistin and polymyxin B: peas in a pod, or chalk and cheese?. Clin Infect Dis 59 (2014), 88–94.
4. [4] Plachouras, D., Karvanen, M., Friberg, L.E., Papadomichelakis, E., Antoniadou, A., Tsangaris, I., et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother 53 (2008), 3430–3436.
5. [5] Gregoire, N., Mimoz, O., Megarbane, B., Comets, E., Chatelier, D., Lasocki, S., et al. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale. Antimicrob Agents Chemother 58 (2014), 7324–7330.
6. [6] Sandri, A.M., Landersdorfer, C.B., Jacob, J., Boniatti, M.M., Dalarosa, M.G., Falci, D.R., et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57 (2013), 524–531.
7. [7] Couet, W., Gregoire, N., Gobin, P., Saulnier, P.J., Frasca, D., Marchand, S., et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 89 (2011), 875–879.
8. [8] Oliveira, M.S., Prado, G.V.B., Costa, S.F., Grinbaum, R.S., Levin, A.S., Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diag Microbiol Infect Dis 65 (2009), 431–434.
9. [9] Phe, K., Lee, Y., McDaneld, P.M., Prasad, N., Yin, T., Figueroa, D.A., et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B. Antimicrob Agents Chemother 58 (2014), 2740–2746.
10. [10] Tuon, F.F., Rigatto, M.H., Lopes, C.K., Kamei, L.K., Rocha, J.L., Zavascki, A.P., Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 43 (2014), 349–352.
11. [11] Rigatto, M.H., Oliveira, M.S., Perdigao-Neto, L.V., Levin, A.S., Carrilho, C.M., Tanita, M.T., et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Chemother 60 (2016), 2443–2449.
12. [12] Akajagbor, D.S., Wilson, S.L., Shere-Wolfe, K.D., Dakum, P., Charurat, M.E., Gilliam, B.L., Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary medical center. Clin Infect Dis 57 (2013), 1300–1303.
13. [13] Abdelraouf, K., Chang, K.T., Yin, T., Hu, M., Tam, V.H., Uptake of polymyxin B into renal cells. Antimicrob Agents Chemother 58 (2014), 4200–4202.
14. [14] Abdelraouf, K., Braggs, K.H., Yin, T., Truong, L.D., Hu, M., Tam, V.H., Characterization of Polymyxin B induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother 56 (2012), 4625–4629.
15. [15] Garonzik, S.M., Li, J., Thamlikitkul, V., Paterson, D.L., Shoham, S., Jacob, J., et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55 (2011), 3284–3294.
16. [16] Colo-Mycin M [package insert], 2006, Monarch Pharmaceuticals, Rochester, MI.
17. [17] European-Medicines-Agency, Polymyxin Artical 31 referral – Annex III Amendments to relevant sections of the summary of product charactersitics and the package leaflets. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Polymyxin_31/WC500176332.pdf, 2014 [Accessed 14 November 2016].
18. [18] Nation, R.L., Li, J., Cars, O., Couet, W., Dudley, M.N., Kaye, K.S., et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 15 (2015), 225–234.
19. [19] Nation, R.L., Garonzik, S.M., Li, J., Thamlikitkul, V., Giamarellos-Bourboulis, E.J., Paterson, D.L., et al. Updated US and European dose recommendations for intravenous colistin: how do they perform?. Clin Infect Dis 62 (2016), 552–558.
20. [20] Ortwine, J.K., Kaye, K.S., Li, J., Pogue, J.M., Colistin: understanding and applying recent pharmacokinetic advances. Pharmacotherapy 35 (2015), 11–16.
21. [21] Kaye KS. Trial for the treatment of extensively drug-resistant gram-negative bacilli. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000–20160920. Available at: URL of the record NLM Identifier: NCT01597973.
22. [22] Polymyxin B [package insert], 2015, Xellia Pharmaceuticals, Big Flats, NY.
23. [23] Nelson, B.C., Eiras, D.P., Gomez-Simmonds, A., Loo, A.S., Satlin, M.J., Jenkins, S.G., et al. Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods. Antimicrob Agents Chemother 59 (2015), 7000–7006.
24. [24] Satlin, M.J., Kubin, C.J., Blumenthal, J.S., Cohen, A.B., Furuya, E.Y., Wilson, S.J., et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 55 (2011), 5893–5899.
25. [25] Rigatto, M.H., Behle, T.F., Falci, D.R., Freitas, T., Lopes, N.T., Nunes, M., et al. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study. J Antimicrob Chemother 70 (2015), 1552–1557.
26. [26] Zavascki, A.P., Manfro, R.C., Maciel, R.A., Falci, D.R., Head and neck hyperpigmentation probably associated with polymyxin B therapy. Ann Pharmacother 49 (2015), 1171–1172.
27. [27] Zavascki, A.P., Schuster, L.F., Duquia, R.P., Histopathological findings of pigmented lesion and recovery of natural skin colour in a patient with polymyxin B-associated diffuse hyperpigmentation. Int J Antimicrob Agents 48 (2016), 579–580.
28. [28] FDA alert 06.28. 2007. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124896.htm.